Concepedia

Author

Emanuela Risi

Hospital of PratoORCID

Also Known As

E Risi, E. De Risi, E. Risi, EMANUELA RISI, Elham Said Ahmed AL Risi, Emanuela Risi, Risi, Emanuela

121

Publications

1.1K

Citations

18

H-Index

33

Concepts

All Affiliations

Hospital of PratoSapienza University of RomeUniversity of FlorenceIstituti Clinici Scientifici MaugeriEuropean Institute of Oncology
ER

About

Emanuela Risi is an author at Hospital of Prato specializing in medicine, oncology, and breast cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

224

2

Health Sciences

3

3

109

3

Nursing

1

1

33

4

Cell Biology

1

1

23

5

Endocrinology

1

1

13

Emanuela Risi

×

18

Publications

625

Citations

14

H-Index

YearCitations

Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

Luca Malorni, Giuseppe Curigliano, Alessandro Marco Minisini,

Annals of Oncology

2018

94

Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population

Christopher D. Hart, Alessia Vignoli, Leonardo Tenori,

Clinical Cancer Research

2017

82

Clinical and Pathological Features of Primary Neuroectodermal Tumor/Ewing Sarcoma of the Kidney

Emanuela Risi, Roberto Iacovelli, Amelia Altavilla,

Urology

2013

79

Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial

Amelia McCartney, Martina Bonechi, Francesca De Luca,

Clinical Cancer Research

2020

54

Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer

Samuel Martel, Elena Poletto, Arlindo R. Ferreira,

The Breast

2017

43

Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study

Matteo Lambertini, Arlindo R. Ferreira, Antonio Di Meglio,

Clinical Breast Cancer

2017

33

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence

Eriseld Krasniqi, Laura Pizzuti, Giacomo Barchiesi,

Journal of Cellular Physiology

2020

33

Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial

Francesca Galardi, Francesca De Luca, Chiara Biagioni,

Breast Cancer Research

2021

32

Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study

Matteo Lambertini, Arlindo R. Ferreira, Francesca Poggio,

The Oncologist

2015

26

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Lorenzo Rossi, Chiara Biagioni, Amelia McCartney,

Breast Cancer Research

2019

24

Page 1